Systemic treatment in hepatocellular carcinoma; 'A small step for man...'

Netherlands Journal of Medicine

Volumn 67, Issue 3, 2009, Pages 86-90

  Witjes, C D M ^a   Verhoef, C ^a   Verheul, H M W ^b   Eskens, F A L M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced hepatocellular carcinoma; Sorafenib; Therapy

Indexed keywords

ALCOHOL; BEVACIZUMAB; CETUXIMAB; ERLOTINIB; GEMCITABINE; OXALIPLATIN; PLACEBO; SORAFENIB; SUNITINIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER MORTALITY; CHEMOEMBOLIZATION; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; LASER COAGULATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER RESECTION; LIVER TRANSPLANTATION; NAUSEA; NONHUMAN; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; REVIEW; SKIN TOXICITY; SYSTEMIC THERAPY; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PYRIDINES;

EID: 63049099301     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Taylor-Robinson SD, Foster GR, Arora S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet. 1997;350:1142-3.
2. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet. 1998;351:214-5.
3. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340;745-50.
4. Verhoef C, Visser O, Man RA de, de Wilt JH, IJzermans JN, Janssen-Heijnen ML. Hepatocellular carcinoma in the Netherlands: Incidence, treatment and survival patterns. Eur J Cancer. 2004;40:1530-8.
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17.
6. Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early, hepatocellular carcinoma: Clues for the best strategy. Hepatology. 200;31:1019-21.
7. Thomas MB, O'Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy For hepatocellular carcinoma: Cytotoxic chemotherapy, targeted therapy and immmunotherapy. Ann Surg Oncol. 2008;15:1008-14.
8. Verhoef C, Man RA de, Zondervan PE, Eijkemans Mi, Tilanus HW, Ijzermans JN. Good outcomes after resection of large hepatocellular carcinoma in the non-cirrhotic liver. Dig Surg. 2004;21:380-6.
9. McCormack L, Petrowsky H, Clavien PA. Surgical therapy of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2005;17:497-503.
10. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9.
11. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001;33:1394-404.
12. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded. Ann Surg. 2007;246:5029.
13. Jansen MC, van Hillegersberg R, Chamuleau RAFM, et al. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. EJSO 2005;31:331-347.
14. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy For small hepatocellular carcinoma. Ann Surg. 2006;243:321-8.
15. Huang GT, Lee PH, Tsang YM, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: A prospective study. Ann Surg. 2005;242:36-42.
16. Lu MD, Kuang M, Liang LJ, et al. Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: A randomized clinical trial. Zhonghua Yi Xue Za Zhi. 2006;86:801-5.
17. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;27:6657-63.
18. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24:4293-300.
19. Zhu AX, Blaszkowskv LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;12 1898-903.
20. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC). Cancer. 2007;109:1384-90.
21. Zhu A. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer. 2008;2:250-9.
22. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol. 2008;18:2992-8.
23. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-109.
24. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
25. Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol. 2008;26(suppl):abstract 4509.
26. Verheul H, Pinedo H. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Can. 2007;7:475-85.
27. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis. 1999;19:329-38.
28. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-711.
29. Amato RJ, Harris P, Dalton M, et al. Phase II trial of intra-patient dose-escalated-sorafenib in patients with metastatic renal cell cancer. J Clin Oncol. 2007;25(suppl):abstract 5026.
30. Shen Y, Shao Y, Hsu C, et al. Phase II study of sorafenib plus tegafur/ uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2008;26(suppl):abstract 15664.
31. Del Prete S, Montello L, Addeo R, et al. Sorafenib plus long-acting octreotide in advanced hepatocellular carcinoma: Preliminary results or a multicenter ongoing study. J Clin Oncol. 2008;26(suppl):abstract 15624.
32. Hakime A, Hines-Peralta A, Peddi H, et al. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: Study in mice. Radiology. 2007;244:464-70.